NFA
JNCE

Nationwide Fund Advisors’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Nationwide Fund Advisors’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-20,523
Closed -$320K – 2383
2017
Q3 		$320K Buy
20,523
+8,577
+72% +$121K ﹤0.01% 2410
2017
Q2 		$168K Buy
11,946
+8,007
+203% +$171K ﹤0.01% 2699
2017
Q1 		$87K Buy
+3,939
New +$83.5K ﹤0.01% 2878

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Nationwide Fund Advisors's JNCE Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2017, closing a stake of 20,523 shares — an estimated $320K sold.

Nationwide Fund Advisors first reported a position in JNCE in Q1 2017 and held it in 3 quarters. The position peaked at $320K in Q3 2017. 83 funds tracked by Wall St. Rank hold JNCE as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 20,523 Jounce Therapeutics, Inc. Common Stock shares in Q4 2017, an estimated $320K.
  • Nationwide Fund Advisors first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 3 quarters.
  • Nationwide Fund Advisors's Jounce Therapeutics, Inc. Common Stock position peaked at $320K in Q3 2017.
  • 83 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.